| Serial Number | 90860823 |
| Word Mark | YONMIRI |
| Filing Date | Monday, August 2, 2021 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, February 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 30, 2023 |
| Name/Portrait Description and/or Consent Statement | The name(s), portrait(s), and/or signature(s) shown in the mark does not identify a particular living individual. |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies |
| Translation of Words in Mark | The word(s) YONMIRI has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, September 28, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Celgene Corporation |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Summit, NJ 07901 |
| Party Name | Celgene Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Summit, NJ 07901 |
| Event Date | Event Description |
| Monday, February 26, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, February 26, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, July 25, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, May 30, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 30, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, May 10, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, April 27, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 26, 2023 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Friday, October 28, 2022 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, October 28, 2022 | FINAL REFUSAL E-MAILED |
| Friday, October 28, 2022 | FINAL REFUSAL WRITTEN |
| Thursday, October 27, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, October 27, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, October 27, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, May 2, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, May 2, 2022 | NON-FINAL ACTION E-MAILED |
| Monday, May 2, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, April 29, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, September 28, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, August 5, 2021 | NEW APPLICATION ENTERED |